Dr Reddy’s in pact with Gilead to sell investigational Covid-19 drug Remdesivir in 127 countries

HYDERABAD: Pharma major Dr Reddy’s Laboratories has entered into an agreement with US-based Gilead Sciences Inc to manufacture and sell Gilead’s investigational anti-viral drug Remdesivir, which was initially developed for Ebola but has now emerged as a potential treatment option for Covid-19.
The non-exclusive licencing agreement will grant Dr Reddy’s the right to register, manufacture and sell Remdesivir in 127 countries including India, Dr Reddy’s said on Saturday.
The Hyderabad-based drug giant said it will receive technology transfer from Gilead for manufacturing the drug and it would carry out the manufacturing scale up and obtain regulatory approval for marketing the drug in the respective countries.
An investigational antiviral therapy developed by Gilead, Remdesivir got Emergency Use Authorization (EUA) from the UD drug watchdog US Food and Drug Administration (USFDA) to treat Covid-19.
A month ago, another Hyderabad-based company Hetero Labs Ltd was among Indian companies like Cipla and Jubilant Lifesciences that entered into a non-exclusive pact with Gilead Sciences for making and marketing Remdesivir in 127 countries, excluding markets like US and Europe.

[Source – Times Of India]


Please enter your comment!
Please enter your name here